



Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications October 2020 CPT® Editorial Panel Meeting

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications (CCAs) that have been submitted for consideration by the CPT Editorial Panel at its October 2020 meeting are listed below. These applications will also be included in the proposed Panel agenda that will be posted to the AMA website on July 31, 2020. This listing includes the code application names, code(s) affected, and a description of the request. **Until such time as the CPT Editorial Panel acts on these requests, the following information is provided for informational purposes only, giving interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).**

This listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP applications is being posted ahead of the full October Panel meeting agenda in order to provide the Molecular Pathology Advisory Group (MPAG) and the Pathology Coding Caucus (PCC) sufficient time to review comments from interested stakeholders prior to making their recommendations to the CPT Editorial Panel.

Codes that contain an 'X' (e.g., 10X24, 23X42, 03X01T) below are temporary codes that are intended to give readers an idea of the proposed placement in the code set of the potential code changes. **These temporary codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed on August 31st of each year. To report the services described by the "X" codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on August 31st of the corresponding year.**

Upon review of these applications, if the reviewer believes that they will need to provide comment on an issue, they should send a request for a copy of the application and associated materials to [Michael Pellegrino](#). This request for review of the agenda materials should contain the identity of the interested party seeking such and a brief summary of the basis for the request (e.g., associated vendor/ industry representative).

Any interested parties wishing to provide written comments on any agenda items should be aware of the following relevant deadlines for provision of written comments on the agenda to ensure comment review by all parties. Additional verbal comments on any issue can be provided in person at the Panel meeting following a statement of conflict of interest. The applicant(s) who submitted the original code change application is automatically considered an interested party and is notified by AMA staff of any request for review submitted by another party.

*Interested party requests will not be processed until the interested party submits a signed confidentiality agreement and disclosure of interest form.

Updated July 8, 2020

- New
- ▲ Revision
- ⊕ Add on
- D Deletion



Please follow the instructions in the correspondence that accompanies the materials.

Pathology/Laboratory and Molecular Pathology, Multianalyte Assays with Algorithmic Analyses, and Genomic Sequencing Procedures Deadlines for Interested Stakeholders	
Request for Code Change Application Materials	July 24
Submission of Written Comments	July 31

During the time between now and the Panel meeting, this listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP CCAs may be modified to reflect changes – additions, deletions or updates. Please check back frequently for the most up to date information. Outcomes on these actions will be listed in the CPT Editorial Panel Summary of Actions for the October 2020 meeting, which will be published on or before November 2, 2020 to the CPT home page of the AMA website <http://www.ama-assn.org/go/panel-actions>.

Name	Code #	Request-Description
Admin MAAA DLBCL Cell of Origin	● 001XM	Request to establish an Administrative Multianalyte Assay with Algorithmic Analysis (MAAA) code 001XM to report oncology (diffuse large B-cell lymphoma [DLBCL]), mRNA, gene expression profiling by fluorescent probe hybridization of 20 genes
Cat III 0564T to Cat I MAAA Cancer Cytotoxicity Assay	D0564T ● 88XX0	Request to establish a Category I Multianalyte Assay with Algorithmic Analysis (MAAA) code 88XX0 to report a cancer cytotoxicity assay and delete Category III code 0564T
MAAA Allograft Rejection Risk	● 815X0	Request to establish a Category I Multianalyte Assay with Algorithmic Analysis (MAAA) code 815X0 to report evaluation of risk of acute cellular rejection of liver/small bowel transplantation in patients less than 21 years old

Updated July 8, 2020

- New
- ▲ Revision
- + Add on
- D Deletion

Name	Code #	Request-Description
MAAA Periprosthetic Joint Infection	●81XX1	Request to establish a Category I Multianalyte Assay with Algorithmic Analysis (MAAA) code 81XX1 report detection of periprosthetic synovial fluid joint infection
MAAA Breast Cancer Risk	● 81XX0 D0067U	Request to establish a Category I Multianalyte Assay with Algorithmic Analysis (MAAA) code 81XX0 report breast cancer risk scores and personalized prophylactic treatment and delete PLA code 0067U
MAAA Breast Cancer Metastasis RNA Sequencing	● 815X1	Request to establish a Category I Multianalyte Assay with Algorithmic Analysis (MAAA) code 815X1 to report oncology, mRNA, microarray with next generation RNA sequencing (RNA seq)
Pathology Clinical Consult	D80500 D80502 ● 80XX0 ● 80XX1 ● 80XX2 ● 80XX3	Revise the Consultations (Clinical Pathology) heading and guidelines; add two new headings and guidelines within the Pathology and Laboratory section; delete codes 80500, 80502; and establish four codes 80XX0, 80XX1, 80XX2, 80XX3 for reporting pathology clinical consultation for moderately complex, highly complex, and prolonged pathology clinical consultation services